Skip To Main Content
Campus
  • Tiede
  • Koulutukset
  • Artikkelit
  • Materiaalit
Campus
  • Tiede
  • Koulutukset
  • Artikkelit
  • Materiaalit

Articles Articles

Järjestä

Suodattimet

Nollaa
  • Terapia-alue
Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Lue lisää
Cardiovascular diseases (CVDs) are the leading cause of death globally<sup>1</sup>

Cardiovascular diseases (CVDs) are the leading cause of death globally

Lue lisää
When to suspect TTP?

When to suspect TTP?

TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.

Lue lisää
Signs and symptoms of aTTP

Signs and symptoms of aTTP

Know the signs and symptoms of acquired TTP (aTTP).

Lue lisää
What is TTP? A rare, life-threatening medical emergency

What is TTP? A rare, life-threatening medical emergency

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.

Lue lisää
Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Lue lisää
How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Lue lisää
Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Lue lisää
The Complex Burden of Autoimmune Type 1 Diabetes

The Complex Burden of Autoimmune Type 1 Diabetes

Lue lisää
Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Lue lisää
The Long-Term Impact of Early-Onset Atopic Dermatitis

The Long-Term Impact of Early-Onset Atopic Dermatitis

A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.

Lue lisää
Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP

Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP

Navigating the Complexities of Smell Loss in Patients with CRSwNP.

Lue lisää